...
首页> 外文期刊>International Journal of Pharmaceutical Sciences and Research >FORMULATION AND CHARACTERIZATION OF CALCIUM SILICATE BASED FLOATING MICROSPHERES OF FAMOTIDINE FOR THE TREATMENT OF PEPTIC ULCER
【24h】

FORMULATION AND CHARACTERIZATION OF CALCIUM SILICATE BASED FLOATING MICROSPHERES OF FAMOTIDINE FOR THE TREATMENT OF PEPTIC ULCER

机译:法替丁的硅酸钙浮游微球的制备与表征

获取原文

摘要

The aim of the present study was to prepare and evaluate floating microspheres consisting of (i) calcium silicate (CS) as porous carrier; (ii) famotidine and (iii) hydroxypropyl methylcellulose (HPMC) and ethylcellulose (EC) as polymers. The floating microspheres were evaluated for particle size, micromeritic properties, percent drug content, in vitro floating behavior, and in vitro drug release. The % yield of formulations (FM1 to FM9) was found to be in the range of 79.51 ± 3.71 to 93.48 ± 0.94 %. Percentage drug content of floating microspheres formulations (FM1 to FM9) was found in the range of 77.25 ± 0.36 to 86.14 ± 2.04 %. In Vitro Buoyancy percentage of the microspheres was found to be 97.5 ± 1.53 %. At pH 1.2, the best formulation FM4 showed maximum drug release (99.26 ± 1.14 %) at the end of 12 hr. The SEM photographs of formulation FM4 showed that the fabricated microspheres were spherical with a smooth surface and exhibited a range of sizes within each batch. The in vivo evaluation for the determination of pharmacokinetic parameters was performed in albino rats. Higher plasma concentration was maintained throughout the study period from the floating microspheres of famotidine. The enhanced bioavailability and elimination half-life observed in the present study may be due to the floating nature of the dosage form. The results suggested that Calcium Silicate is a useful carrier for the development of floating and sustained release preparations. The results suggested that Calcium Silicate is a useful carrier for the development of floating and sustained release preparations.
机译:本研究的目的是制备和评估由(i)硅酸钙(CS)作为多孔载体组成的漂浮微球; (ii)法莫替丁和(iii)羟丙基甲基纤维素(HPMC)和乙基纤维素(EC)作为聚合物。评估了漂浮的微球的粒径,微质量特性,药物含量百分比,体外漂浮行为和体外药物释放。发现制剂(FM1-FM9)的%收率在79.51±3.71至93.48±0.94%的范围内。浮动微球制剂(FM1至FM9)的药物含量百分比范围为77.25±0.36至86.14±2.04%。发现微球的体外浮力百分比为97.5±1.53%。在pH 1.2下,最佳配方FM4在12小时结束时显示出最大的药物释放(99.26±1.14%)。配方FM4的SEM照片显示,所制造的微球为球形,表面光滑,每批内都显示出一系列尺寸。在白化病大鼠中进行用于确定药代动力学参数的体内评估。在整个研究期间,法莫替丁的漂浮微球体均保持较高的血浆浓度。在本研究中观察到的提高的生物利用度和消除半衰期可能是由于剂型的漂浮性。结果表明硅酸钙是用于漂浮和持续释放制剂开发的有用载体。结果表明硅酸钙是用于漂浮和持续释放制剂开发的有用载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号